Press Release

According to Research for Markets, the Global Cancer Diagnostics market is expected to grow from $8.54 billion in 2016 to reach $22.41 billion by 2023 with a CAGR of 14.8 %. Increasing incidence of cancer diseases, growing awareness about health care, and recent technological advancements in diagnostic devices are some of the factors propelling the market growth. In addition, favorable government reimbursement policies, increasing investments in research and development activities are some other factors boosting the market growth during the forecast period. On the other hand, high costs of diagnostic devices, strict regulations for new product approvals are the factors limiting the market growth.

Get  a  Sample copy of this report: https://www.researchformarkets.com/sample/cancer-diagnostics-global-market-5011

Globally, cancer is the most emerging disease in recent times. Cervical, breast, liver, blood, kidney, colorectal, pancreatic, ovarian, melanoma, and lung cancers are types of cancers persisting in humans. Diagnosing at early stage can cure the disease and limit the disease severity. Research institutes have the high adoption rate of cancer diagnostic devices due to heavy funding from government and private institutions.

North America is estimated to be the dominant one among all, due to developed healthcare infrastructure, government initiatives towards public health care that are expected to drive this dominance. Asia Pacific region is predicted to grow at higher CAGR during the forecast period. The growth is attributed to rise in medical tourism market, increase in prevalence of cancer disease in countries such as Japan, China, and India are favoring the Asia Pacific market growth.

Cancer Diagnostics
Cancer Diagnostics

Some of the key players in global Cancer Diagnostics market include Abbott Diagnostics, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMérieux, C.R. Bard, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare (A Subsidiary of General Electric Company), Hologic,Inc., Illumina, Inc., Koninklijke Philips N.V., Qiagen, Roche Diagnostics, Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc.

Technologies Covered:
• Instrument-Based
• Platform-Based Diagnostics
• Tumor Biomarkers Tests

Applications Covered:
• Cervical Cancer
• Breast Cancer
• Liver Cancer
• Blood Cancer
• Kidney Cancer
• Colorectal Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Melanoma
• Lung Cancer
• Other Cancers

End Users Covered:
• Cancer Research Institutes
• Diagnostic Laboratories
• Hospital Associated Labs
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

Get Discount  on Report:  https://www.researchformarkets.com/discount/cancer-diagnostics-global-market-5011

About us:

Research for Markets indulge in detailed and diligent research on different markets, trends and emerging opportunities in the successive direction to cater to your business needs. We have established the pillars of our flourishing institute on the grounds of Credibility and Reliability. RFM delve into the markets across Asia Pacific, North America, South America, Europe, Middle East and Africa.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Info:

Name: Research For Markets

Email: [email protected]

Phone: +44 8000-4182-37

www.researchformarkets.com